https://scholars.lib.ntu.edu.tw/handle/123456789/469780
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chen Y.-P. | en_US |
dc.contributor.author | Chang K.-C. | en_US |
dc.contributor.author | Tseng W.-K. | en_US |
dc.contributor.author | Yin W.-H. | en_US |
dc.contributor.author | Chen J.-W. | en_US |
dc.contributor.author | Lee Y.-T. | en_US |
dc.contributor.author | CHAU-CHUNG WU | en_US |
dc.creator | Chen Y.-P.;Chang K.-C.;Tseng W.-K.;Yin W.-H.;Chen J.-W.;Lee Y.-T.;Chau-Chung Wu | - |
dc.date.accessioned | 2020-03-04T09:03:10Z | - |
dc.date.available | 2020-03-04T09:03:10Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1011-6842 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84886923743&partnerID=40&md5=fcfb5facd5783817c01383bd95c3d41e | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/469780 | - |
dc.description.abstract | Purpose: We aimed to ascertain whether increased rosuvastatin dose is non-inferior to concomitant fenofibrate and rosuvastatin therapy in patients with diabetes or atherosclerosis with metabolic syndrome. Methods: After treatment with rosuvastatin 5 mg/day for 12 weeks, 112 patients were randomly assigned to receive either 10 mg/day rosuvastatin (group A) or 80 mg/day supra-film coated fenofibrate plus 5 mg/day rosuvastatin (group B). The therapy effects were evaluated by measuring the serum lipid profile, liver and muscle enzymes, and renal function after the treatment period. Results: After the treatment, the total cholesterol, high-density-lipoprotein cholesterol (HDL-C), non HDL-C, low-density-lipoprotein cholesterol (LDL-C), and triglyceride were comparable between the 2 groups. The change in the non-HDL-C were -7.39 ± 26.58 (-6.62%) and -0.68 ± 24.49 (-1.19%) mg/dl (p = 0.28); and the change in the triglyceride were -36.61 ± 62.51 (-14.00%) and -44.77 ± 77.35 (-23.17%) mg/dl (p = 0.64), respectively. While 41.37% of group A and 38.69% of group B achieved their LDL-C goal (< 100 mg/dl) (p = 0.79), 37.26% of group A and 42.31% of group B achieved their triglyceride goal (< 150 mg/dl) (p = 0.53), respectively. The changes in the serum transaminase and creatinine phosphokinase were similar between the 2 groups. Conclusions: After 5 mg/day of rosuvastatin, the lipid profile in patients with diabetes or atherosclerotic vascular diseases with metabolic syndrome could be improved by increasing rosuvastatin dose, and the resultant decrease of non-HDL and triglyceride were similar to those obtained with combination therapy. Both therapies were safe and feasible. | - |
dc.relation.ispartof | Acta Cardiologica Sinica | - |
dc.subject | Combination therapy; Diabetes; Fenofibrate; Metabolic syndrome; Monotherapy; Statin | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | aminotransferase; cholesterol; creatinine; fenofibrate; high density lipoprotein cholesterol; lipid; low density lipoprotein cholesterol; phosphotransferase; rosuvastatin; triacylglycerol; adult; aminotransferase blood level; article; atherosclerosis; cholesterol blood level; clinical trial; diabetes mellitus; drug dose increase; female; human; kidney function; lipid blood level; major clinical study; male; metabolic syndrome X; monotherapy; therapy effect; treatment duration; triacylglycerol blood level | - |
dc.title | Increased rosuvastatin dose versus concomitant fenofibrate and rosuvastatin therapy to achieve lipid goal in patients with diabetes or atherosclerosis with metabolic syndrome | en_US |
dc.type | journal article | en |
dc.identifier.scopus | 2-s2.0-84886923743 | - |
dc.relation.pages | 421-428 | - |
dc.relation.journalvolume | 29 | - |
dc.relation.journalissue | 5 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Medical Education and Bioethics | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-8191-475X | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學教育暨生醫倫理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。